ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

830
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Insights

AI in Medical Affairs: How Pharma Is Becoming a Real-Time Scientific Intelligence System

Executive Summary Medical affairs is undergoing a structural transformation that goes far beyond digital enablement or workflow automation. It is...
Insights

Are Pharmaceutical Companies Moving Too Fast With AI Adoption?

Executive Summary Artificial intelligence is rapidly becoming embedded across nearly every layer of the pharmaceutical industry. Drug discovery, clinical trial...
Commercial

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Liminatus Pharma, a company specializing in cancer immunotherapies, has agreed to give up shares valued at $320 million to...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you